Emergence of RTK/RAS/PI3K pathway alterations in trastuzumab-refractory HER2-positive esophagogastric (EG) tumors

Authors :: Brittanie M Millang
Michael F. Berger
Yaelle Tuvy
Jamie Riches
David H. Ilson
David B. Solit
Nikolaus Schultz
Jaclyn F. Hechtman
Sasinya N. Scott
Nancy Bouvier
David P. Kelsen
Maurizio Scaltriti
Barry S. Taylor
Francisco Sanchez-Vega
Pau Castel
Geoffrey Y. Ku
Efsevia Vakiani
Yelena Y. Janjigian
Ritika Kundra
Matthew Margolis
Source :: Journal of Clinical Oncology. 34:11608-11608
Publication Year :: 2016
Publisher :: American Society of Clinical Oncology (ASCO), 2016.
Abstract: 11608Background: Up to 30% of EG adenocarcinomas harbor ERBB2 (HER2) gene amplification or oncoprotein over-expression. While trastuzumab prolongs survival in patients with Stage IV HER2+ EG tumors...

Subjects :: Cancer Research
business.industry
03 medical and health sciences
0302 clinical medicine
Oncology
Refractory
Trastuzumab
030220 oncology & carcinogenesis
Gene duplication
medicine
Cancer research
030211 gastroenterology & hepatology
In patient
skin and connective tissue diseases
business
Stage iv
neoplasms
PI3K/AKT/mTOR pathway
medicine.drug

Full Text Access

Tools